Detection of seizurogenic compounds in human and rat neurons in vitro: A multi-laboratory, multi-model assessment
2026
Open access, peer-reviewed publications ensure that knowledge is a public good. HESI believes that accessible research is critical for equitable engagement, diverse collaboration, and increased interdisciplinary conversation. We strive to achieve open access on all publications, and more than 500 publications from HESI programs have been published in the last decade.
2026
Pharmaceutical Biology, 2026
Gene Therapy, 2026
Birth Defects Research, 2026
HESI Global’s Developmental and Reproductive Toxicology (DART) Committee is pleased to share a newly published paper that proposes a shift from routinely excluding pregnant and breastfeeding individuals from clinical trials to a more proactive, evidence-based inclusion strategy.
Birth Defects Research, 2026
Biologic therapeutics, including monoclonal antibodies, are increasingly important tools in modern medicine. For patients who are pregnant or may become pregnant, understanding how these therapies may transfer across the placenta is essential for interpreting developmental toxicity studies and informing human safety ...
Environmental and Molecular Mutagenesis, 2026
This paper advanced mutagenicity risk assessment with standardized benchmark response (BMR) for error-corrected sequencing (ECS) technologies.
hesi@hesiglobal.org
Phone: +1-202-659-8404
Fax: +1-202-659-8403
740 15th Street NW, Suite 600
Washington, DC 20005
Sign up for our monthly e-newsletter.